Chinese domestic antibody drug industry in 2017 counts 200 companies with 22 approved species and about 200 drug applications

Sina Publisher has published a detailed map on Chinese antibody producers. The authors come to the conclusion that a) the number of producers is consolidating, b) autoimmune diseases and cancer application accounts for 78% market share of antibody drugs, c) for the next 10 years, domestic producers will focus on the development of generic or me-better antibodies

China Bio news release, August 28, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny